Marinus Pharmaceuticals’ (MRNS) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note published on Tuesday, Benzinga reports. They currently have a $13.00 price target on the biopharmaceutical company’s stock.

Several other research analysts have also recently issued reports on the stock. JMP Securities reiterated a market outperform rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a report on Monday. HC Wainwright reissued a buy rating and set a $11.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Truist Financial restated a buy rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. Oppenheimer upgraded Marinus Pharmaceuticals from a market perform rating to an outperform rating and set a $6.00 price target on the stock in a report on Monday. Finally, StockNews.com upgraded Marinus Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, September 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Hold and an average target price of $8.83.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS opened at $1.73 on Tuesday. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.15 and a current ratio of 2.28. The firm has a market cap of $95.04 million, a PE ratio of -0.66 and a beta of 1.13. The firm’s 50 day simple moving average is $1.40 and its 200-day simple moving average is $2.67. Marinus Pharmaceuticals has a one year low of $1.05 and a one year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The firm had revenue of $8.06 million for the quarter, compared to the consensus estimate of $9.05 million. During the same period last year, the firm earned ($0.61) earnings per share. As a group, equities analysts predict that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRNS. Point72 DIFC Ltd acquired a new stake in Marinus Pharmaceuticals in the second quarter worth about $28,000. SG Americas Securities LLC acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter worth approximately $34,000. AQR Capital Management LLC grew its position in Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Marinus Pharmaceuticals during the 2nd quarter valued at approximately $64,000. Finally, Values First Advisors Inc. raised its holdings in shares of Marinus Pharmaceuticals by 501.8% in the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 52,257 shares during the last quarter. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.